The Value-Based Pricing and Market Access of Valbenazine: A Cost Effective Evaluation in Japan

By Staff Writer

November 29, 2023

Valbenazine Market Access

The Centre for Outcomes Research and Economic Evaluation for Health (C2H) is an esteemed department of the National Institute of Public Health in Japan, established in 2018. The organisation conducts rigorous academic research on cost-effectiveness evaluations and plays a crucial role in the official evaluation process. In a nation where public healthcare expenditure is continually increasing, C2H’s work is invaluable. They strive to balance the cost and outcome of healthcare technologies, providing crucial data and materials for evidence-based health policy. The ultimate goal is to enhance the sustainability of the public healthcare system. C2H is a beacon of knowledge for experts conducting cost-effectiveness evaluations, offering guidelines and analytical tools. Furthermore, they also guide manufacturers in conducting scientifically sound analyses and help citizens and healthcare professionals understand the value and implications of their evaluations. Below are some insights to Valbenazine market access.

Valbenazine: A Breakthrough in Tardive Dyskinesia Treatment

In May 2023, Valbenazine was reimbursed and its drug price was set at JPY 2331.2 for a Dysval® capsule 40mg in Japan, determined via the Similar Efficacy Comparison Method with a 5% premium. This pricing strategy is an example of dynamic pricing, a common practice in pharmaceutical pricing strategy. The drug was designated for the Cost-effectiveness Evaluation with an H2 classification, reflecting its significant value story.

Target Population and Treatment Options

The target population for Valbenazine is patients with tardive dyskinesia whose symptoms have not improved sufficiently by reducing or discontinuing drugs for underlying diseases. Given the limited treatment options for this group, the comparator for the cost-effectiveness evaluation was “watchful waiting”.

Evaluating the Additional Benefits of Valbenazine

The manufacturer conducted a systematic review of randomised controlled trials to evaluate the drug’s additional benefits. This review included a mixed-model meta-analysis that compared Valbenazine with a placebo. The results showed that Valbenazine significantly improved patients’ symptoms. This reaffirms the value-based healthcare benefits of the drug. 

Cost-Effectiveness Analysis of Valbenazine

The manufacturer conducted a cost-utility analysis using a microsimulation model. This model accounted for responses from interventions, prescription of antipsychotic drugs, and recurrence of underlying diseases. Interestingly, the results of this analysis further substantiated the benefits of Valbenazine, demonstrating its cost-effectiveness and aligning with the principles of value-based healthcare 2024. 

Reference url

Recent Posts

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

drug price regulation
      

Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Challenges

💊 Curious about the future of drug pricing in the U.S.?

The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.

Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.

#SyenzaNews #pharmaceuticals #healthcarepolicy

AI Patient Education
       

AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

🤔 Are AI solutions ready to revolutionize pediatric patient education?

A recent study compared ChatGPT and Gemini in generating educational materials for common pediatric conditions, revealing intriguing insights into content depth, readability, and reliability. While both tools have their merits, there’s significant room for improvement in making AI-generated content accessible and effective for all families.

Curious to learn more about the implications for health literacy and the future of AI in healthcare? Click to read the full article!

#SyenzaNews #AIinHealthcare #HealthTech #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.